---
created: 2025-04-13
updated: 2025-04-13T10:52
id: go<^!PC(z^
specialty: neuro
specialty_id: 215
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::05-pharmacology::03-toxicities-&-side-effects::07-drug-reactions---neurologic
  - "source/ak-step1-v11:": 
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::01-epilepsy-therapy
  - "source/ak-step1-v11:": 
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::01-epilepsy-therapy::vigabatrin
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::14-neuro::03-epilepsy-carbamazepine,-phenytoin,-gabapentin,-tiagabine
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::13-antiepileptics::vigabatrin
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::06-neuro/psych::04-mood-stabilizers-&-antiepileptic-drugs::05-carbamazepine,-phenytoin,-gabapentin,-tiagabine,-vigabatrin
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - source/ak-step1-v11::^systems::neuro::pharmacology"
type: flashcard
---

# Question
What serious adverse effect may be caused by vigabatrin use?    **Permanent vision loss (black box warning)**

---

# Answer
